Nivolumab

for the recommended dosage information, as appropriate. Table 2: Recommended Dosages for OPDIVO QVANTIG in Combination with Other Therapeutic Agents Indication Recommended OPDIVO QVANTIG Dosage Duration of Therapy Advanced renal cell carcinoma 600 mg nivolumab and 10,000 units hyaluronidase every 2 weeks or 1,200 mg nivolumab and 20,000 units hyaluronidase every 4 weeks Administer OPDIVO QVANTIG in combination with cabozantinib 40 mg orally once daily without food OPDIVO QVANTIG: Until disease progression, unacceptable toxicity, or up to 2 years Cabozantinib: Until disease progression or unacceptable toxicity Neoadjuvant treatment of resectable non-small cell lung cancer 900 mg nivolumab and 15,000 units hyaluronidase with platinum-doublet chemotherapy on the same day every 3 weeks In comb...

treatment of resectable non-small cell lung cancer Neoadjuvant: 900 mg nivolumab and 15,000 units hyaluronidase with platinum-doublet chemotherapy on the same day every 3 weeks Neoadjuvant: in combination with platinum-doublet chemotherapy until disease progression or unacceptable toxicity,

for up to 4 cycles Adjuvant: 1,200 mg nivolumab and 20,000 units hyaluronidase every 4 weeks Adjuvant: following neoadjuvant therapy and surgery, administer as a single agent until disease progression, recurrence, or unacceptable toxicity, for up to 13 cycles (up to 1 year) First-line unresectable or metastatic urothelial carcinoma 900 mg nivolumab and 15,000 units hyaluronidase every 3 weeks Administer OPDIVO QVANTIG in combination with cisplatin and gemcitabine on the same day every 3 weeks In combination with cisplatin and gemcitabine for up to 6 cycles 600 mg nivolumab and 10,000 units hyaluronidase every 2 weeks or 1,200 mg nivolumab and 20,000 units hyaluronidase every 4 weeks After completing up to 6 cycles of combination therapy, administer as single agent until disease progression...